Clinical Trial Update: Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update for XC001 gene therapy notes the study in coronary artery disease patients undergoing CABG is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• XC001

Snippet

Sponsor: XyloCor Therapeutics, Inc. | Conditions: Coronary Artery Disease (CAD) | Phase 2 | Status: NOT_YET_RECRUITING